Petter O. Veiby
Publications by Year
Research Areas
Glioma Diagnosis and Treatment, Prostate Cancer Treatment and Research, Epigenetics and DNA Methylation, Ubiquitin and proteasome pathways, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment(2018)441 cited
- → Inhibition of NEDD8-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover(2011)152 cited
- → A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function(2011)151 cited
- → A generic approach for simultaneous measurements of total antibody and cleavable antibody-conjugated drug by LC/MS/MS(2017)19 cited
- → Antibody–drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies(2016)16 cited
- → Abstract PR12: MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC), demonstrates antitumor activity alone and in combination with gemcitabine in human pancreatic cancer xenograft models expressing GCC.(2013)9 cited
- → 329 The Investigational Drug MLN0264 First-in-human, First in Class ADC Targeting GCC: Phase I Dose-escalation Study and Supportive Scientific Rationale(2012)4 cited
- → Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2(2018)3 cited
- → Abstract 498: ZL-1201, a differentiated CD47 therapeutic antibody with improved hematological safety profile(2021)2 cited
- → Abstract 2594: Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor(2022)2 cited